JPH09509186A - ガスを含む微細粒子、微細粒子を含む薬剤、超音波診断における薬剤の使用並びに粒子及び薬剤の製造方法 - Google Patents
ガスを含む微細粒子、微細粒子を含む薬剤、超音波診断における薬剤の使用並びに粒子及び薬剤の製造方法Info
- Publication number
- JPH09509186A JPH09509186A JP7522099A JP52209995A JPH09509186A JP H09509186 A JPH09509186 A JP H09509186A JP 7522099 A JP7522099 A JP 7522099A JP 52209995 A JP52209995 A JP 52209995A JP H09509186 A JPH09509186 A JP H09509186A
- Authority
- JP
- Japan
- Prior art keywords
- fine particles
- weight
- gas
- surfactant
- particles according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000010419 fine particle Substances 0.000 title claims description 98
- 239000002245 particle Substances 0.000 title claims description 43
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 238000003745 diagnosis Methods 0.000 title claims description 8
- 239000003814 drug Substances 0.000 title description 24
- 229940079593 drug Drugs 0.000 title description 23
- 239000004094 surface-active agent Substances 0.000 claims abstract description 49
- -1 polyoxyethylene Polymers 0.000 claims abstract description 40
- 239000000725 suspension Substances 0.000 claims abstract description 26
- 239000000126 substance Substances 0.000 claims abstract description 23
- 239000000194 fatty acid Substances 0.000 claims abstract description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 17
- 229930195729 fatty acid Natural products 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 14
- 239000002961 echo contrast media Substances 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 12
- 229930006000 Sucrose Natural products 0.000 claims abstract description 7
- 150000002191 fatty alcohols Chemical class 0.000 claims abstract description 7
- 229920000642 polymer Polymers 0.000 claims abstract description 7
- 229930182558 Sterol Natural products 0.000 claims abstract description 5
- 239000000654 additive Substances 0.000 claims abstract description 5
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 5
- 150000003432 sterols Chemical class 0.000 claims abstract description 5
- 235000003702 sterols Nutrition 0.000 claims abstract description 5
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 4
- 244000068988 Glycine max Species 0.000 claims abstract description 4
- 229930186217 Glycolipid Natural products 0.000 claims abstract description 4
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 4
- 239000011859 microparticle Substances 0.000 claims abstract description 3
- 239000002872 contrast media Substances 0.000 claims description 28
- 239000012298 atmosphere Substances 0.000 claims description 21
- WMIYKQLTONQJES-UHFFFAOYSA-N hexafluoroethane Chemical compound FC(F)(F)C(F)(F)F WMIYKQLTONQJES-UHFFFAOYSA-N 0.000 claims description 21
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims description 17
- 229950003332 perflubutane Drugs 0.000 claims description 17
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 16
- 229930182830 galactose Natural products 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 13
- 229920006395 saturated elastomer Polymers 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 11
- 235000002639 sodium chloride Nutrition 0.000 claims description 10
- 150000002366 halogen compounds Chemical class 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 claims description 8
- 229960004065 perflutren Drugs 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000007789 sealing Methods 0.000 claims description 8
- 229920000858 Cyclodextrin Polymers 0.000 claims description 7
- 230000036760 body temperature Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 150000002772 monosaccharides Chemical class 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 235000013681 dietary sucrose Nutrition 0.000 claims description 6
- 150000002016 disaccharides Chemical class 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229960004793 sucrose Drugs 0.000 claims description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 239000006194 liquid suspension Substances 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 4
- 239000004927 clay Substances 0.000 claims description 4
- 150000008282 halocarbons Chemical class 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 4
- WSJULBMCKQTTIG-OWOJBTEDSA-N (e)-1,1,1,2,3,4,4,4-octafluorobut-2-ene Chemical compound FC(F)(F)C(/F)=C(\F)C(F)(F)F WSJULBMCKQTTIG-OWOJBTEDSA-N 0.000 claims description 3
- ZVJOQYFQSQJDDX-UHFFFAOYSA-N 1,1,2,3,3,4,4,4-octafluorobut-1-ene Chemical compound FC(F)=C(F)C(F)(F)C(F)(F)F ZVJOQYFQSQJDDX-UHFFFAOYSA-N 0.000 claims description 3
- PBWHQPOHADDEFU-UHFFFAOYSA-N 1,1,2,3,3,4,4,5,5,5-decafluoropent-1-ene Chemical compound FC(F)=C(F)C(F)(F)C(F)(F)C(F)(F)F PBWHQPOHADDEFU-UHFFFAOYSA-N 0.000 claims description 3
- LGPPATCNSOSOQH-UHFFFAOYSA-N 1,1,2,3,4,4-hexafluorobuta-1,3-diene Chemical compound FC(F)=C(F)C(F)=C(F)F LGPPATCNSOSOQH-UHFFFAOYSA-N 0.000 claims description 3
- QVHWOZCZUNPZPW-UHFFFAOYSA-N 1,2,3,3,4,4-hexafluorocyclobutene Chemical compound FC1=C(F)C(F)(F)C1(F)F QVHWOZCZUNPZPW-UHFFFAOYSA-N 0.000 claims description 3
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 239000004341 Octafluorocyclobutane Substances 0.000 claims description 3
- 235000019482 Palm oil Nutrition 0.000 claims description 3
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 239000000032 diagnostic agent Substances 0.000 claims description 3
- 229940039227 diagnostic agent Drugs 0.000 claims description 3
- 239000008151 electrolyte solution Substances 0.000 claims description 3
- 150000004676 glycans Chemical class 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- WBCLXFIDEDJGCC-UHFFFAOYSA-N hexafluoro-2-butyne Chemical compound FC(F)(F)C#CC(F)(F)F WBCLXFIDEDJGCC-UHFFFAOYSA-N 0.000 claims description 3
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 claims description 3
- JWDVRIOQNXFNES-UHFFFAOYSA-N n,1,1,1-tetrafluoro-n-(trifluoromethyl)methanamine Chemical compound FC(F)(F)N(F)C(F)(F)F JWDVRIOQNXFNES-UHFFFAOYSA-N 0.000 claims description 3
- BCCOBQSFUDVTJQ-UHFFFAOYSA-N octafluorocyclobutane Chemical compound FC1(F)C(F)(F)C(F)(F)C1(F)F BCCOBQSFUDVTJQ-UHFFFAOYSA-N 0.000 claims description 3
- 235000019407 octafluorocyclobutane Nutrition 0.000 claims description 3
- 229920001542 oligosaccharide Polymers 0.000 claims description 3
- 150000002482 oligosaccharides Chemical class 0.000 claims description 3
- 239000002540 palm oil Substances 0.000 claims description 3
- 229960004692 perflenapent Drugs 0.000 claims description 3
- NJCBUSHGCBERSK-UHFFFAOYSA-N perfluoropentane Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F NJCBUSHGCBERSK-UHFFFAOYSA-N 0.000 claims description 3
- 229920000570 polyether Polymers 0.000 claims description 3
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 3
- 229920001282 polysaccharide Polymers 0.000 claims description 3
- 239000005017 polysaccharide Substances 0.000 claims description 3
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000001587 sorbitan monostearate Substances 0.000 claims description 3
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 3
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 claims description 3
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 3
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical class C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
- PWWKERINVYVSIE-UHFFFAOYSA-N 1,1,3,3-tetrafluoropropa-1,2-diene Chemical compound FC(F)=C=C(F)F PWWKERINVYVSIE-UHFFFAOYSA-N 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 2
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 150000002972 pentoses Chemical class 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- 239000012047 saturated solution Substances 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 229930193551 sterin Natural products 0.000 claims description 2
- 150000004043 trisaccharides Chemical class 0.000 claims description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 abstract description 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract 1
- 229920001214 Polysorbate 60 Polymers 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 239000007789 gas Substances 0.000 description 66
- 230000000694 effects Effects 0.000 description 17
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 8
- 238000005538 encapsulation Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000002604 ultrasonography Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000005240 left ventricle Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000005086 pumping Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229940021013 electrolyte solution Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Polymers OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- JNYAEWCLZODPBN-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)oxolane-3,4-diol Polymers OCC(O)C1OCC(O)C1O JNYAEWCLZODPBN-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 229910018503 SF6 Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- AZSZCFSOHXEJQE-UHFFFAOYSA-N dibromodifluoromethane Chemical compound FC(F)(Br)Br AZSZCFSOHXEJQE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 229910052756 noble gas Inorganic materials 0.000 description 1
- 150000002835 noble gases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- JNYAEWCLZODPBN-CTQIIAAMSA-N sorbitan Polymers OCC(O)C1OCC(O)[C@@H]1O JNYAEWCLZODPBN-CTQIIAAMSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- SFZCNBIFKDRMGX-UHFFFAOYSA-N sulfur hexafluoride Chemical compound FS(F)(F)(F)(F)F SFZCNBIFKDRMGX-UHFFFAOYSA-N 0.000 description 1
- 229960000909 sulfur hexafluoride Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C19/00—Acyclic saturated compounds containing halogen atoms
- C07C19/08—Acyclic saturated compounds containing halogen atoms containing fluorine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.人体温度においてガス体になる成分並びに少なくとも一つの界面活性物質 及び少なくとも一つの非界面活性物質の混合から成る微細粒子を含み、人体温度 におけるガス体成分として水への溶解性が空気よりも悪い物質又は物質混合物を 含むことを特徴とする超音波診断用薬剤を製造するための調剤。 2.界面活性物質としてリン脂質、ステロール、糖脂質、エトキシル化したダ イズステリン、ポリオキシエチレン脂肪酸エステル、エトキシル化又は硫酸化し た脂肪族アルコール、ポリオキシエチレンポリオキシプロピレン−ポリマー、サ ッカロースエステル、ポリオキシエチレン脂肪酸エーテル、ポリオキシエチレン 、飽和又は不飽和脂肪酸又はこれらの塩、脂肪族アルコール、モノ−、ジ−及び トリグリセリド、脂肪酸エステル、キシログリセリド、アルキルアリールポリエ ーテルアルコール、フッ素化脂肪族アルコール、エトキシル化又は硫酸化したフ ッ素化脂肪族アルコール、フッ素化アルキルアルコキシラート及び/又はポリオ キシエトキシル基を入れたソルビタン脂肪酸エステルを0.01から10重量%までの 量で含むことを特徴とする請求項1記載の微細粒子。 3.界面活性物質として飽和又は不飽和のC12−C26−脂肪酸、ポリオキシエ チレン−ポリオキシプロピレン−ポリマー及び/又はエトキシル化したフッ素化 脂肪族アルコールを10重量%までの濃度で含むことを特徴とする請求項1又は2 記載の微細粒子。 4.非界面活性固体物質としてシクロデキストリン、これらの誘導体、単糖類 、二糖類、三糖類、オリゴ糖類、多糖類、ペントース、ポリオール及び/又は無 機塩又は有機塩を90〜99.999重量%の濃度で含むことを特徴とする請求項1〜3 のいずれか1項記載の微細 粒子。 5.非界面活性固体物質としてガラクトース、ラクトース、サッカロース、マ ルトース又はα−,β−,γ−シクロデキストリン又はこれらの誘導体を90〜99 .999重量%の濃度で含むことを特徴とする請求項1〜4のいずれか1項記載の微 細粒子。 6.非界面活性固体物質として粘土粒子又は酸化鉄粒子を500μm未満の粒径 で含むことを特徴とする請求項1記載の微細粒子。 7.非界面活性固体物質として植物に由来する不溶性粒子を含むことを特徴と する請求項1記載の微細粒子。 8.微細粒子が 0.001から10重量%までのステアリン酸ブチル及び99.999から 90重量%までのガラクトースの混合から成ることを特徴とする請求項1〜5のい ずれか1項記載の微細粒子。 9.微細粒子が 0.001から10重量%までダイズ油サッカロースグルセリド及び 99.999から90重量%までのガラクトースの混合から成ることを特徴とする請求項 1〜5のいずれか1項記載の微細粒子。 10.微細粒子が 0.001から10重量%までのポリエチレングリコールソルビタン モノステアラート及び99.999から90重量%までのガラクトースの混合から成るこ とを特徴とする請求項1〜5のいずれか1項記載の微細粒子。 11.微細粒子が 0.001から10重量%までのパーム油キシリド及び99.999から90 重量%までのガラクトースの混合から成ることを特徴とする請求項1〜5のいず れか1項記載の微細粒子。 12.人体温度においてガス体になる成分として少なくとも一つのハロゲン化炭 化水素を含むことを特徴とする請求項1〜11のいずれか1項記載の微細粒子。 13.ハロゲン化合物が少なくとも一つのフッ素原子を含むことを特徴とする請 求項1〜11のいずれか1項記載の微細粒子。 14.ハロゲン化合物としてテトラフルオロアレン、ヘキサフルオロ−1,3− ブタジエン、デカフルオロブタン、ペルフルオロ−1−ブテン、ペルフルオロ− 2−ブテン、ペルフルオロ−2−ブチン、オクタフルオロシクロブタン、ペルフ ルオロシクロブテン、ペルフルオロジメチルアミン、ヘキサフルオロエタン、テ トラフルオロエチレン、ペンタフルオロチオ(トリフルオロ)メタン、テトラフ ルオロメタン、ペンフルオロペンタン、ペルフルオロ−1−ペンテン、ペルフル オロプロパン及び/又はペルフルオロプロピレンが考慮されることを特徴とする 請求項1〜11のいずれか1項記載の微細粒子。発明によりヘキサフルオロエタン 、デカフルオロブタン及び/又はペルフルオロペンタンが優先して含まれる。 15.ハロゲン化合物としてヘキサフルオロエタン、デカフルオロブタン及び/ 又はペルフルオロプロパンを含むことを特徴とする請求項1〜11のいずれか1項 記載又は請求項13記載の微細粒子。 16.生理的適合性をもつ液状懸濁媒質の中に請求項1〜15のいずれか1項記載 の微細粒子を含み、必要な場合には医薬技術で通常使用される添加剤を加えた超 音波用造影剤。 17.生理的適合性をもつ懸濁液媒質として水、生理電解質溶液、グリセリン、 ポリエチレングリコールのような一価又は多価アルコールの水溶液又はプロピレ ングリコールメチルエステルの水溶液又は単糖類又は二糖類の水溶液を含む請求 項16記載の超音波用造影剤。 18.添加剤として適合性のある界面活性剤又はヒドロコロイド状分散剤を含む 請求項16記載の超音波用造影剤。 19.a)密閉栓を備え、無菌条件のもとで内容物を取り出すことができ、液状 懸濁媒質が満たされている第1容器及び b)密閉栓を備え、無菌条件のもとで懸濁液媒質を注入すること ができ、請求項1〜15のいずれか1項記載の微細粒子及び微細粒子に含有される ガスと同一のガス又は混合ガスで満たされ、ここで第2容器の体積を測ると第1 容器の懸濁液媒質が完全に2容器の体積を占めることができるような第2容器か ら構成され、微細粒子及びガスを含む超音波用造影剤を製造するためのキット。 20.生理的適合性をもつ界面活性物質及び生理的適合性をもつ非界面活性固体 物質を混合して得た微細粒子を生理的適合性をもつ担体液体に混ぜ合わせ懸濁が 均一になるまで振とうすることを特徴とする微細粒子及びガスを含む超音波診断 用の造影剤を製造する方法。 21.a)水に溶解した非界面活性物質に界面活性物質のアルコール性溶液を攪 拌しながら添加して再結晶し、ここで各溶液はハロゲン化合物で飽和され、又は b)微細粒子が少なくとも90重量%の非界面活性物質及び10重量%までの界面 活性物質から成り、1から30気圧までの圧力のもとで1時間から6日間まで所望 のハロゲン化ガスを送り、その前に望ましくは他のガスを真空にして取り除き、 又は c)微細粒子が少なくとも90重量%の非界面活性物質及び10重量%までの界面 活性物質から成り、ハロゲン化ガスのもとでエアジェット粉砕機を稼働して望み のサイズに粉砕し、又は d)非界面活性物質がハロゲン化ガスの飽和溶液から再結晶化され、引き続い て前述のハロゲン化ガスの雰囲気のもとで界面活性物質と共に粉砕され、又は e)少なくとも90重量%の非界面活性物質及び10重量%までの界面活性物質か らなる微細粒子を、ハロゲン化ガスで飽和した媒質に溶解し、引き続いて溶液か ら再結晶化する ことを特徴とする請求項1〜15のいずれか1項記載の微細粒子を製 造する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4406474.8 | 1994-02-23 | ||
DE4406474A DE4406474A1 (de) | 1994-02-23 | 1994-02-23 | Gas enthaltende Mikropartikel, diese enthaltende Mittel, deren Verwendung in der Ultraschalldiagnostik, sowie Verfahren zur Herstellung der Partikel und Mittel |
PCT/EP1995/000484 WO1995022994A1 (de) | 1994-02-23 | 1995-02-10 | Gas enthaltende mikropartikel, diese enthaltende mittel, deren verwendung in der ultraschalldiagnostik, sowie verfahren zur herstellung der partikel und mittel |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09509186A true JPH09509186A (ja) | 1997-09-16 |
JP4242448B2 JP4242448B2 (ja) | 2009-03-25 |
Family
ID=6511397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52209995A Expired - Fee Related JP4242448B2 (ja) | 1994-02-23 | 1995-02-10 | ガスを含む微細粒子、微細粒子を含む薬剤、超音波診断における薬剤の使用並びに粒子及び薬剤の製造方法 |
Country Status (24)
Country | Link |
---|---|
US (1) | US6306366B1 (ja) |
EP (2) | EP0855186A3 (ja) |
JP (1) | JP4242448B2 (ja) |
KR (1) | KR970701067A (ja) |
CN (1) | CN1141595A (ja) |
AT (1) | ATE205727T1 (ja) |
AU (1) | AU701797B2 (ja) |
CA (1) | CA2183968A1 (ja) |
CZ (1) | CZ287115B6 (ja) |
DE (2) | DE4406474A1 (ja) |
DK (1) | DK0744961T3 (ja) |
ES (1) | ES2162912T3 (ja) |
FI (1) | FI963279A0 (ja) |
HU (1) | HUT74516A (ja) |
IL (1) | IL112617A (ja) |
MX (1) | MX9603619A (ja) |
NO (1) | NO312497B1 (ja) |
NZ (1) | NZ281212A (ja) |
PL (1) | PL315972A1 (ja) |
PT (1) | PT744961E (ja) |
RU (1) | RU2137502C1 (ja) |
SK (1) | SK108696A3 (ja) |
WO (1) | WO1995022994A1 (ja) |
ZA (1) | ZA951498B (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008501684A (ja) * | 2004-06-04 | 2008-01-24 | アキュスフィア, インコーポレイテッド | 超音波造影剤の投薬処方物 |
JP2009018284A (ja) * | 2007-07-13 | 2009-01-29 | Kao Corp | 微細気泡前駆体の製造方法 |
JP2011140527A (ja) * | 2011-04-20 | 2011-07-21 | Acusphere Inc | 超音波造影剤の投薬処方物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5804162A (en) * | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
DE19602930A1 (de) * | 1996-01-18 | 1997-07-24 | Schering Ag | Poröse Matrices aus niedermolekularen Substanzen zur Genierung stabiler Gasblasensuspensionen, deren Verwendung als Ultraschallkontrastmittel sowie Verfahren zu deren Herstellung |
NZ335265A (en) * | 1996-10-21 | 2000-07-28 | Nycomed Imaging As | Gas containing contrast agents that may be co-administered with vasodilator drugs to enhance differences in return signal intensity from normal and hypoperfused myocardial tissue contrast agents |
DE19805012A1 (de) * | 1998-02-07 | 1999-08-12 | Thomas Gieselmann | Kontrastmittel zur Verwendung als Diagnostikum bei bildgebenden Verfahren sowie seine Herstellung |
US7838034B2 (en) * | 2002-07-30 | 2010-11-23 | Grunenthal Gmbh | Intravenous pharmaceutical form of administration |
US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
US10369343B2 (en) | 2006-06-30 | 2019-08-06 | Biocompatibles Uk Limited | Apparatus and method to convey a fluid |
US20110217553A1 (en) * | 2007-12-20 | 2011-09-08 | Warner Isiah M | Frozen Ionic Liquid Microparticles and Nanoparticles, and Methods for their Synthesis and Use |
CN101721719B (zh) * | 2008-10-28 | 2011-09-28 | 温州医学院 | 超声造影剂及其制备方法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3834705A1 (de) * | 1988-10-07 | 1990-04-12 | Schering Ag | Ultraschallkontrastmittel aus gasblaeschen und fettsaeure enthaltenden mikropartikeln |
DE3313947A1 (de) * | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
US5141738A (en) * | 1983-04-15 | 1992-08-25 | Schering Aktiengesellschaft | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof |
DE3313946A1 (de) * | 1983-04-15 | 1984-10-18 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mikropartikel und gasblaeschen enthaltende ultraschall-kontrastmittel |
JPS61275420A (ja) | 1985-05-31 | 1986-12-05 | Toray Ind Inc | ポリエステル糸条の直接紡糸延伸方法 |
DE3529195A1 (de) | 1985-08-14 | 1987-02-26 | Max Planck Gesellschaft | Kontrastmittel fuer ultraschalluntersuchungen und verfahren zu seiner herstellung |
DE3741199A1 (de) * | 1987-12-02 | 1989-08-17 | Schering Ag | Verwendung von ultraschallkontrastmitteln fuer die ultraschall-lithotripsie |
JP2907911B2 (ja) * | 1988-02-05 | 1999-06-21 | シエーリング アクチエンゲゼルシヤフト | 超音波造影剤、その製造方法及び該超音波造影剤からなる診断又は治療用製剤 |
US5425366A (en) | 1988-02-05 | 1995-06-20 | Schering Aktiengesellschaft | Ultrasonic contrast agents for color Doppler imaging |
DE4004430A1 (de) | 1990-02-09 | 1991-08-14 | Schering Ag | Aus polyaldehyden aufgebaute kontrastmittel |
IN172208B (ja) | 1990-04-02 | 1993-05-01 | Sint Sa | |
US5445813A (en) | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
US5556610A (en) | 1992-01-24 | 1996-09-17 | Bracco Research S.A. | Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method |
US5055119A (en) | 1990-09-13 | 1991-10-08 | Owens-Corning Fiberglas Corporation | Method and apparatus for forming migration free glass fiber packages |
US5147631A (en) | 1991-04-30 | 1992-09-15 | Du Pont Merck Pharmaceutical Company | Porous inorganic ultrasound contrast agents |
WO1992021382A1 (en) | 1991-06-03 | 1992-12-10 | Holmes, Michael, John | Improvements in or relating to contrast agents |
GB9200387D0 (en) | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
GB9200391D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
GB9200388D0 (en) | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
US5302372A (en) | 1992-07-27 | 1994-04-12 | National Science Council | Method to opacify left ventricle in echocardiography |
JPH08502979A (ja) | 1992-11-02 | 1996-04-02 | ドレクセル ユニバーシティー | 表面活性剤で安定化された微小気泡混合物、その製造方法およびその使用方法 |
US5362478A (en) | 1993-03-26 | 1994-11-08 | Vivorx Pharmaceuticals, Inc. | Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell |
CA2166459C (en) * | 1993-07-02 | 2000-03-28 | Karel J. Lambert | Methods for making encapsulated microspheres from heat denatured protein |
CA2164813C (en) * | 1993-07-30 | 2009-11-24 | Ernest G. Schutt | Stabilized microbubble compositions for ultrasound |
US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
JPH1193037A (ja) | 1997-09-12 | 1999-04-06 | Asahi Chem Ind Co Ltd | 撚糸織物 |
JPH11172526A (ja) | 1997-11-26 | 1999-06-29 | Asahi Chem Ind Co Ltd | 低熱応力ポリエステル繊維及びその紡糸方法 |
JPH11189925A (ja) | 1997-12-22 | 1999-07-13 | Toray Ind Inc | 芯鞘複合繊維の製造方法 |
JP3167677B2 (ja) | 1998-04-23 | 2001-05-21 | 旭化成株式会社 | ポリエステル異形断面繊維 |
-
1994
- 1994-02-23 DE DE4406474A patent/DE4406474A1/de not_active Withdrawn
-
1995
- 1995-02-10 ES ES95909702T patent/ES2162912T3/es not_active Expired - Lifetime
- 1995-02-10 SK SK1086-96A patent/SK108696A3/sk unknown
- 1995-02-10 RU RU96119318A patent/RU2137502C1/ru active
- 1995-02-10 CA CA002183968A patent/CA2183968A1/en not_active Abandoned
- 1995-02-10 MX MX9603619A patent/MX9603619A/es unknown
- 1995-02-10 EP EP98250140A patent/EP0855186A3/de not_active Ceased
- 1995-02-10 AU AU18087/95A patent/AU701797B2/en not_active Ceased
- 1995-02-10 HU HU9602300A patent/HUT74516A/hu unknown
- 1995-02-10 KR KR1019960704607A patent/KR970701067A/ko not_active Application Discontinuation
- 1995-02-10 PT PT95909702T patent/PT744961E/pt unknown
- 1995-02-10 CZ CZ19962421A patent/CZ287115B6/cs not_active IP Right Cessation
- 1995-02-10 WO PCT/EP1995/000484 patent/WO1995022994A1/de not_active Application Discontinuation
- 1995-02-10 JP JP52209995A patent/JP4242448B2/ja not_active Expired - Fee Related
- 1995-02-10 AT AT95909702T patent/ATE205727T1/de not_active IP Right Cessation
- 1995-02-10 NZ NZ281212A patent/NZ281212A/en unknown
- 1995-02-10 DK DK95909702T patent/DK0744961T3/da active
- 1995-02-10 CN CN95191752A patent/CN1141595A/zh active Pending
- 1995-02-10 DE DE59509618T patent/DE59509618D1/de not_active Revoked
- 1995-02-10 PL PL95315972A patent/PL315972A1/xx unknown
- 1995-02-10 EP EP95909702A patent/EP0744961B1/de not_active Revoked
- 1995-02-12 IL IL11261795A patent/IL112617A/xx not_active IP Right Cessation
- 1995-02-23 ZA ZA951498A patent/ZA951498B/xx unknown
-
1996
- 1996-08-22 NO NO19963501A patent/NO312497B1/no not_active IP Right Cessation
- 1996-08-22 FI FI963279A patent/FI963279A0/fi unknown
-
1998
- 1998-08-06 US US09/129,953 patent/US6306366B1/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008501684A (ja) * | 2004-06-04 | 2008-01-24 | アキュスフィア, インコーポレイテッド | 超音波造影剤の投薬処方物 |
JP2009018284A (ja) * | 2007-07-13 | 2009-01-29 | Kao Corp | 微細気泡前駆体の製造方法 |
JP2011140527A (ja) * | 2011-04-20 | 2011-07-21 | Acusphere Inc | 超音波造影剤の投薬処方物 |
Also Published As
Publication number | Publication date |
---|---|
NO963501D0 (no) | 1996-08-22 |
ATE205727T1 (de) | 2001-10-15 |
NO312497B1 (no) | 2002-05-21 |
EP0744961A1 (de) | 1996-12-04 |
PL315972A1 (en) | 1996-12-23 |
AU701797B2 (en) | 1999-02-04 |
MX9603619A (es) | 1997-04-30 |
WO1995022994A1 (de) | 1995-08-31 |
DK0744961T3 (da) | 2001-12-10 |
EP0855186A3 (de) | 1999-01-27 |
IL112617A0 (en) | 1995-05-26 |
AU1808795A (en) | 1995-09-11 |
NO963501L (no) | 1996-10-22 |
FI963279A (fi) | 1996-08-22 |
IL112617A (en) | 1999-12-22 |
JP4242448B2 (ja) | 2009-03-25 |
NZ281212A (en) | 1998-06-26 |
SK108696A3 (en) | 1997-05-07 |
FI963279A0 (fi) | 1996-08-22 |
DE4406474A1 (de) | 1995-08-24 |
EP0744961B1 (de) | 2001-09-19 |
CA2183968A1 (en) | 1995-08-31 |
RU2137502C1 (ru) | 1999-09-20 |
CZ287115B6 (en) | 2000-09-13 |
HUT74516A (en) | 1997-01-28 |
ZA951498B (en) | 1995-12-07 |
ES2162912T3 (es) | 2002-01-16 |
US6306366B1 (en) | 2001-10-23 |
HU9602300D0 (en) | 1996-10-28 |
PT744961E (pt) | 2002-03-28 |
CZ242196A3 (en) | 1996-11-13 |
DE59509618D1 (de) | 2001-10-25 |
EP0855186A2 (de) | 1998-07-29 |
CN1141595A (zh) | 1997-01-29 |
KR970701067A (ko) | 1997-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR970001433B1 (ko) | 소형 기포 및 지방산-함유 미립자를 함유하는 초음파 조영제 | |
FI81264B (fi) | Mikropartiklar och gasblaosor innehaollande ultraljudkontrastmedel. | |
US5141738A (en) | Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof | |
US4466442A (en) | Carrier liquid solutions for the production of gas microbubbles, preparation thereof, and use thereof as contrast medium for ultrasonic diagnostics | |
FI81265C (fi) | Mikropartiklar och gasblaosor innehaollande ultraljudkontrastmedel. | |
CA2127705C (en) | Improvements in or relating to contrast agents | |
JPH11506960A (ja) | 超音波造影に使用するための核形成及び活性化方法 | |
NZ246589A (en) | Contrast agent: carbohydrate microparticles which generate microbubbles | |
JP4242448B2 (ja) | ガスを含む微細粒子、微細粒子を含む薬剤、超音波診断における薬剤の使用並びに粒子及び薬剤の製造方法 | |
CN107233583B (zh) | 一种具有超长持续时间的超声造影剂及其制备方法 | |
JP2000504317A (ja) | 気泡懸濁物と超音波造影剤への応用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20051025 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20051020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060120 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060306 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060425 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061219 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070316 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070619 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081125 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20081225 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120109 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |